Linneo Health launches high THC content medicinal cannabis varieties into major global markets
New 22% and 25% THC content medicinal cannabis strains have been shipped to customers in Germany and the UK, two of the largest global medicinal cannabis markets.
Madrid, Spain, 22 March 2023: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the strengthening of its medicinal cannabis offering with the addition of two cannabis varieties with high tetrahydrocannabinol (THC) content. These new strains, with 22% and 25% THC content, complement the Company’s existing broad portfolio and first batches have been shipped to customers in Germany and the UK, two of the leading medicinal cannabis markets.
Linneo’s newly developed cannabis varieties have been designed to contain higher THC levels, which may be beneficial in the development of medicinal cannabis products targeting a broader range of therapeutic areas. They add to the Company’s diversified product portfolio, which includes medicinal cannabis varieties with different sativa to indica ratios that customers can tailor for patients’ needs in a broad spectrum of indications. This is another demonstration of Linneo executing on its strategy to continually develop medicinal cannabis strains that address the market needs.
The new varieties come from well understood cultivation processes and possess premium genetics, with additional exclusive features including a high total terpene content over 3%, providing higher chemical diversity.
Enrique Borras, Commercial Director at Linneo Health, said: “These new varieties of medicinal cannabis expand Linneo’s offering and demonstrate our commitment to continuous innovation in order to provide our customers with the cutting edge in medicinal cannabis, to improve human health and wellbeing.
“There is a need for greater innovation into tailored medicinal cannabis strains that can cater to patients’ health needs, and we are delighted to be playing a role in this growing field by providing our new strains to customers in Germany and the UK, the two largest medicinal cannabis markets in Europe. These strains are an indicator of our ongoing portfolio expansion and we look forward to sharing further news on our increasing product offering.”
- ENDS -
Enquiries:
Linneo Health
Don Bellamy, CEO
Tel: +34 91 700 20 90
Consilium Strategic Communications
Amber Fennell / David Daley / Maya Bennison
Linneo@consilium-comms.com
Tel: +44 (0) 20 3709 5700
About Linneo Health
Linneo Health is a Europe based, global leader in the research, EU-GMP certified manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. The world’s only vertically integrated medicinal cannabis supplier, no other company has Linneo’s 90-year heritage in the manufacturing and movement of controlled substances. Linneo is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling.
Linneo Health is setting the benchmark for standards and customer service in medicinal cannabis. Through ongoing investment in one of the most advanced quality control laboratories in Europe, and by applying industry-leading cultivation techniques, Linneo is the trusted partner to address the needs of customers today and, with significant expansion capabilities, the demands of tomorrow. With an unrivalled focus on quality and driven by the firm belief that people around the world deserve to be treated with cannabis medicine of the highest standard, Linneo brings cutting edge innovation in medicinal cannabis to partners, to deliver better patient outcomes and improve lives. www.linneohealth.com